News All the latest news and information about the care, research, teaching and management we do at Vall d’Hebron Barcelona Hospital Campus. Don't miss any details! Fulltext search Search Dr. Marc Miravitlles, new vice president of the ERS and future president (2026-2027) 17/09/2024 Dr. Eva Polverino receives the ERS Teaching Award 05/09/2024 Vall d'Hebron highlights the potential of synbiotics to control irritability 22/07/2024 Dr Marc Miravitlles named honorary member of SEPAR 10/06/2024 Genetic basis of ADHD and autism spectrum disorder impacts on school performance 31/05/2024 A genetic study indicates that ADHD is associated with lower life expectancy 09/05/2023 Demonstrated the safety of therapy with viruses to combat multidrug-resistant bacteria 13/04/2023 Largest genetic study in ADHD identifies new genome regions associated with the disorder 24/02/2023 Four Vall d’Hebron mental health projects awarded in the 2021 TV3 La Marató charity event 03/11/2022 Vall d'Hebron hosts a meeting of the EXIMIOUS project 23/05/2022 Dr Amanda Rodríguez presents her book 'Siente lo que comes' 05/04/2022 New study shows the relationship between insomnia and ADHD improvement 03/03/2022 New report with the collaboration of Vall d’Hebron calls for clearer definition of treatment-resistant depression 15/12/2021 Vall d'Hebron studies the effectiveness of online interventions for cannabis addiction in young people 07/12/2021 A Vall d'Hebron study allows optimizing the treatment of patients with severe damage in their lungs after COVID-19 18/11/2021 Families with transplanted children feel more understood due to the widespread use of prevention measures, such as masks 15/09/2021 The Multidisciplinary Pancreatic Cancer Committee has already carried out 686 assessments on 305 patients 05/09/2021 Two Vall d’Hebron professionals are ambassadors of the ERS International Congress, the world's most important congress on respiratory diseases 05/09/2021 Vall d'Hebron participates in a study that identifies 33 new genetic variants associated with bipolar disorder 16/05/2021 Vall d’Hebron enrolls the first patient in a Phase IIb clinical trial by Oryzon for Borderline Personality Disorder 28/03/2021 Pagination 1 2 Next › Next page Last » Last page